UH professor's work may yield heart drug
May 26, 2017 | 75° | Check Traffic

Top News

UH professor’s work may yield heart drug


A new biotechnology firm has licensed technology from the University of Hawaii with the intention of developing new drugs to treat and prevent heart failure.

Makai Biotechnology LLC will be using intellectual property developed by Alexander Stokes, an assistant professor of cell and molecular biology at the John A. Burns School of Medicine and licensed via the UH Office of Technology Transfer & Economic Development.

Stokes’ lab at the medical school recently published data from pre-clinical trials showing that inhibition of a biochemical sensor can protect the heart from dangerous changes associated with enlargement of the heart and subsequent heart failure.

Makai Biotechnology was founded by Stokes and David Watu-mull, CEO of the life sciences company Cardax.

The university holds an interest in Makai Biotechnology and may receive future revenue derived from its licensed property.

No comments
By participating in online discussions you acknowledge that you have agreed to the TERMS OF SERVICE. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. Because only subscribers are allowed to comment, we have your personal information and are able to contact you. If your comments are inappropriate, you may be banned from posting. To report comments that you believe do not follow our guidelines, email commentfeedback@staradvertiser.com.